Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01585415
Title Vemurafenib and White Blood Cell Therapy for Advanced Melanoma
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

melanoma

Therapies

Vandetanib

Age Groups: adult
Covered Countries USA

Additional content available in CKB BOOST